Evidence map›Paper›PMID 31166201›Full record

ReviewClinical and translational gastroenterology2019

Pancreatitis: TIGAR-O Version 2 Risk/Etiology Checklist With Topic Reviews, Updates, and Use Primers.

David C Whitcomb, North American Pancreatitis Study Group

Open access · goldAbstract readReview
In one paragraph

Review in Clinical and translational gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 122 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Health Inequities in Pancreatic Disorders in the Black/African American Community.Journal of racial and ethnic health disparities · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Idiopathic chronic pancreatitis: clinical highlights.Therapeutic advances in gastroenterology · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Clinical Features and Prevalence of Osteosarcopenia in Chronic Pancreatitis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025
    Observational
  15. Article
  16. Article
  17. Treatment Strategies for Chronic Pancreatitis (CP).Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  18. Article
  19. Article
  20. Chronic and Idiopathic Pancreatitis-A Personalized Treatment Approach.United European gastroenterology journal · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

David C WhitcombUniversity of Pittsburgh, Division of Gastroenterology, Hepatology and Nutritions, Department of Medicine, Cell Biology and Molecular Physiology, and Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania.
North American Pancreatitis Study Group
University of Pittsburgh · US

Funding

UPMC Clinical Center for the Study of Chronic Pancreatitis and DiabetesU01DK108306 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Frederico G. S. Toledo, Dhiraj Yadav · 2015 to 2026
$6.4M
NIDDK NIH HHS U01 DK108306
6 · The paper itself

Abstract

The Toxic-metabolic, Idiopathic, Genetic, Autoimmune, Recurrent and severe acute pancreatitis and Obstructive (TIGAR-O) Pancreatitis Risk/Etiology Checklist (TIGAR-O_V1) is a broad classification system that lists the major risk factors and etiologies of recurrent acute pancreatitis, chronic pancreatitis, and overlapping pancreatic disorders with or without genetic, immunologic, metabolic, nutritional, neurologic, metaplastic, or other features. New discoveries and progressive concepts since the 2001 TIGAR-O list relevant to understanding and managing complex pancreatic disorders require an update to TIGAR-O_V2 with both a short (S) and long (L) form. The revised system is designed as a hierarchical checklist for health care workers to quickly document and track specific factors that, alone or in combinations, may contribute to progressive pancreatic disease in individual patients or groups of patients and to assist in treatment selection. The rationale and key clinical considerations are summarized for each updated classification item. Familiarity with the structured format speeds up the completion process and supports thoroughness and consideration of complex or alternative diagnoses during evaluation and serves as a framework for communication. The structured approach also facilitates the new health information technologies that required high-quality data for accurate precision medicine. A use primer accompanies the TIGAR-O_V2 checklist with rationale and comments for health care workers and industries caring for patients with pancreatic diseases.

Indexed as

ChecklistAcute DiseaseChronic DiseaseHumansPancreatitisRecurrenceRisk Factors

Identifiers

PMID31166201
PMCPMC6613863
OpenAlexW2949501310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.